Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a Phase 2 study titled ‘A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma.’ The study aims to evaluate the efficacy of rocatinlimab in reducing asthma exacerbations, which could significantly impact treatment options for asthma patients.
The study tests rocatinlimab, an experimental drug administered via subcutaneous injection, across three different doses against a placebo. The goal is to determine the optimal dose that effectively reduces asthma symptoms.
This study is randomized and double-blind, meaning neither participants nor investigators know who receives the drug or placebo. It follows a parallel intervention model, focusing on treatment as its primary purpose.
The study began on May 24, 2024, with its primary completion estimated for a future date. The latest update was submitted on June 25, 2025, indicating ongoing progress.
This update could positively influence Amgen’s stock performance by showcasing its commitment to innovative asthma treatments, potentially boosting investor confidence. Competitors in the respiratory treatment market will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.